ARS Pharma Refocuses Strategy As Q2 Revenue Hits $33.7M
ARS Pharmaceuticals (SPRY) reported Q2 2026 revenue of $33.7M, up from $15.7M a year earlier, driven by $26.2M U.S. net product revenue from neffy. Net loss widened to $62.3M ($0.63/share). The company cut broad consumer ads, targeted high-volume prescribers, appointed Meg Smith CCO, and expects H2 2026 SG&A and R&D of $114M-$126M.
How this was made
The 30-second read
Why it matters
Q2 results show strong neffy traction (U.S. net product revenue and prescriber growth) alongside a major strategic shift to targeted provider engagement and significant H2 cost reductions, with management guiding cash-flow breakeven by end-2027.
Market read
Traders can reprice SPRY based on the combination of a large Q2 revenue jump, a prescriber expansion, and explicit H2 cash-based expense reductions tied to a cash-flow breakeven target.
What to watch
Collaboration revenue fell to $0.1M and supply revenue rose from $0.3M to $7.4M, so investors may scrutinize sustainability of partner-driven supply versus core neffy demand.
Background
ARS Pharma is commercializing neffy, a needle-free intranasal epinephrine for allergic reactions and anaphylaxis, and is also running ARS-2 for acute flares of chronic spontaneous urticaria.
Ticker impact
ARS Pharma reported Q2 2026 revenue of $33.7M, including $26.2M U.S. net product revenue from neffy, and cut cash-based spend outlook for H2.
Likely supportive for SPRY on expectations of operating leverage, but volatility remains tied to commercial execution and continued neffy growth.
Revenue more than doubled year over year, prescriber count surged to 16,000+, and management guided a >40% reduction in cash-based SG&A and R&D in H2, targeting cash-flow breakeven by end-2027.
Market effects
Highlights commercial execution and operating-efficiency focus in specialty pharma, potentially reinforcing investor preference for near-term cash-flow paths.
No specific regional spillover beyond U.S. prescribing and FDA-labeled expansion.
European marketing of EURneffy is referenced, but the guidance and drivers are primarily U.S.-centric.
Counterpoint
Despite revenue growth, operating expenses remain very high and the net loss widened to $62.3M, so the breakeven timeline may be execution-dependent.
Key entities
- companyARS Pharmaceuticals, Inc.
Reported Q2 2026 results, revised H2 expense outlook, and outlined a commercial strategy shift to drive neffy adoption.
- productneffy (epinephrine nasal spray)
Needle-free epinephrine treatment whose U.S. net product revenue drove the quarter’s growth.
- executiveMeg Smith
Appointed Chief Commercial Officer effective August 17, 2026, to lead the commercial organization.
- pipeline_programARS-2
Intranasal epinephrine program for acute flares of chronic spontaneous urticaria, with interim Phase 2b data expected in Q1 2027.
